Skip to main content

Stream every public session from the 27th annual Global Conference right here on our website.

Mark Blumling

< Back to previous page

Mark Blumling

CEO, President and Founder, Headlands Research
Mark Blumling

A passionate advocate of healthcare and life sciences innovation, Mark has devoted his career to improving population health and patient outcomes. Mark is CEO, President and Founder at Headlands Research, an international clinical trial site organization. Mark was previously CEO of Genos, a healthcare big data company (which he co-founded and which was acquired in 2017), CEO of Relevare Pharmaceuticals (a drug development pharmaceutical company based in San Francisco and Australia), and Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired in 2015). Mark began his career in the Office of Science & Technology at SmithKline Beecham, where he was involved in the creation and development of new business ventures, and at Orchid Biosciences (NASDAQ: ORCH), where he helped lead the company’s successful turnaround. Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.